T cell–mediated anti-tumor immunotherapy emerges as a promising treatment for human malignancies, in which CD8+ T cells [cytotoxic T lymphocytes (CTLs)] represent a major of the cell-mediated anti-tumor response via providing host immune protection against intracellular pathogens and cancers (7, 8). This evidence concerns the gene CD8A and neoplasm.